Advertisement

Topics

Canagliflozin delays increase in certain CV biomarkers in T2DM

08:30 EDT 2 Aug 2017 | Medical Xpress

(HealthDay)—For patients with type 2 diabetes mellitus (T2DM), treatment with canagliflozin delays the increase in serum N-terminal pro-B type natriuretic peptide (NT-proBNP) and high-sensitivity troponin I (hsTnI) compared with placebo, according to a study published in the Aug. 8 issue of the Journal of the American College of Cardiology.

Original Article: Canagliflozin delays increase in certain CV biomarkers in T2DM

NEXT ARTICLE

More From BioPortfolio on "Canagliflozin delays increase in certain CV biomarkers in T2DM"

Quick Search
Advertisement
 

Relevant Topic

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...